# The Safety and Tolerability of Engensis (VM202) in Patients With Charcot-Marie-Tooth Disease Subtype 1A (CMT1A)

> **NCT05361031** · PHASE1,PHASE2 · COMPLETED · sponsor: **Helixmith Co., Ltd.** · enrollment: 12 (actual)

## Conditions studied

- CMT

## Interventions

- **BIOLOGICAL:** Engensis (VM202)

## Key facts

- **NCT ID:** NCT05361031
- **Lead sponsor:** Helixmith Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-21
- **Primary completion:** 2021-09-09
- **Final completion:** 2022-02-22
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05361031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05361031, "The Safety and Tolerability of Engensis (VM202) in Patients With Charcot-Marie-Tooth Disease Subtype 1A (CMT1A)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05361031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*